Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects.
about
The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A ReviewAn excitatory role for peripheral EP3 receptors in bladder afferent functionIonic storm in hypoxic/ischemic stress: can opioid receptors subside it?Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia.Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.Visceral pain: the neurophysiological mechanismPeripheral kappa-opioid agonists for visceral pain.Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.Early-in-life bladder inflammation alters U50,488H but not morphine-induced inhibition of visceromotor responses to urinary bladder distensionEarly in life bladder inflammation alters opioid peptide content in the spinal cord and bladder of adult female ratsOpioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications.Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug designFrom Acupuncture to Interaction between δ-Opioid Receptors and Na (+) Channels: A Potential Pathway to Inhibit Epileptic Hyperexcitability.Biotransformation of beta-endorphin and possible therapeutic implications.The κ-opioid receptor agonist U-50488 blocks Ca2+ channels in a voltage- and G protein-independent manner in sensory neurons.Effect of GABA(B) receptor agonist on distension-sensitive pelvic nerve afferent fibers innervating rat colon.
P2860
Q26851158-00E5E3CE-2131-4385-82AC-1727D426255DQ28571705-2FE89FF9-E6A2-4E36-95BB-074F68E6E9C4Q33746364-5DC16198-F57E-4E51-B882-FED26BD14A20Q34274321-04EE88FA-7481-4F4C-8105-37F9FCFA5B74Q35048680-46CB7166-A040-45D8-9A6F-520A872CB551Q35164413-883B17BE-6D51-45F1-ADD3-F581D009C8B7Q35722680-204F80B3-E7C7-4EAD-AB55-64252BCF2896Q35752958-ED1AF896-2E16-468A-B0F1-DD5545FFB8D8Q36572347-D93BF684-20EB-4BD3-A56D-C6BCCB329A6BQ36921219-62B5B67A-F8F3-4B0C-AE77-BF7B3D6A283BQ38911748-21C05970-20A3-4EB9-A792-AC8F30BCDE5CQ39522869-4F1CA76F-D878-48DC-9902-10413C33F21FQ40191419-3EB1730E-0E34-412F-BC0D-7D9DCA8D5237Q41964452-1CBEBE5E-33E7-4E13-A77E-1186A0DD81CBQ42142075-B4ABF6DF-CF83-4EFE-A3DB-0CB14375F268Q44185458-2FD27EE5-1869-4271-B5C0-3715ECE2AE55
P2860
Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Sodium channel blocking action ...... ceral antinociceptive effects.
@en
Sodium channel blocking action ...... ceral antinociceptive effects.
@nl
type
label
Sodium channel blocking action ...... ceral antinociceptive effects.
@en
Sodium channel blocking action ...... ceral antinociceptive effects.
@nl
prefLabel
Sodium channel blocking action ...... ceral antinociceptive effects.
@en
Sodium channel blocking action ...... ceral antinociceptive effects.
@nl
P2093
P2860
P356
P1476
Sodium channel blocking action ...... ceral antinociceptive effects.
@en
P2093
P2860
P304
P356
10.1152/JN.00624.2001
P407
P577
2002-03-01T00:00:00Z